Isolation and Characterization of Norfloxacin-Resistant Mutants Of

Total Page:16

File Type:pdf, Size:1020Kb

Isolation and Characterization of Norfloxacin-Resistant Mutants Of ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1986, p. 248-253 Vol. 30, No. 2 0066-4804/86/080248-06$02.00/0 Copyright © 1986, American Society for Microbiology Isolation and Characterization of Norfloxacin-Resistant Mutants of Escherichia coli K-12 KEIJI HIRAI,'* HIROSHI AOYAMA,1 SEIGO SUZUE,1 TSUTOMU IRIKURA,1 SHIZUKO IYOBE,2 AND SUSUMU MITSUHASHI3 Central Research Laboratories, Kyorin Pharmaceutical Co. Ltd., Nogi-machi, Shimotsuga-gun, Tochigi,l Department of Microbiology, School ofMedicine, Gunma University, Maebashi, Gunma,2 and Episome Institute, Fujimi, Gunma,3 Japan Received 30 December 1985/Accepted 19 May 1986 We isolated spontaneous mutants from Escherichia coli K-12 with low-level resistance to norfloxacin. These mutants were classified into the following three types on the basis of their properties: (i) NorA appeared to result for mutation in the gyrA locus for the A subunit of DNA gyrase; (ii) NorB showed low-level resistance to quinolones and other antimicrobial agents (e.g., cefoxitin, chloramphenicol, and tetracycline), and the norB gene was considered to map at about 34 min on the E. coli K-12 chromosome; (iii) NorC was less susceptible to norfloxacin and ciprofloxacin but was hypersusceptible to hydrophobic quinolones such as nalidixic acid and rosoxacin, hydrophobic antibiotics, dyes, and detergents. Susceptibility to bacteriophages and the hydropho- bicity of the NorC cell surface also differed from that of the parent strain. The norC gene was located near the lac locus at 8 min on the E. coli K-12 chromosome. Both NorB and NorC mutants had a lower rate of norfloxacin uptake, and it was found that the NorB mutant was altered in OmpF porin and that the NorC mutant was altered in both OmpF porin and apparently in the lipopolysaccharide structure of the outer membrane. Many new quinolones showing potent antibacterial activ- lated from E. coli KL-16 by plating on nutrient agar plates ity against gram-positive and gram-negative bacteria, includ- containing norfloxacin. Strain KJC-1, a gIpT derivative of ing Pseudomonas aeruginosa, have been developed recently JC1552, was made by fosfomycin selection as described (12, 18, 33, 34). They also show high antibacterial activity previously (21). The phages Tula and TuIb were kindly against nalidixic acid-resistant strains including mutational provided by S. Mizushima of Nagoya University, Nagoya, resistant strains such as gyrA and nalB mutants of Esche- Japan. richia coli K-12 (14, 28). There is incomplete cross- Drugs. AM-833, ciprofloxacin, norfloxacin, ofloxacin, resistance between the new quinolones and nalidixic acid oxolinic acid, pipemidic acid, piromidic acid, and rosoxacin (14, 17, 28, 35). were synthesized by Central Research Laboratories of The high antibacterial activity of new quinolones (e.g., Kyorin Pharmaceutical Co., Ltd. Ampicillin, cefoxitin, norfloxacin and ciprofloxacin) might be due to their strong chloramphenicol, cloxacillin, fosfomycin, gentamicin, nali- inhibitory action on DNA gyrase, which is the target enzyme dixic acid, novobiocin, streptomycin, and tetracycline were of quinolones (K. Sato, Y. Inoue, T. Fujii, H. Aoyama, M. obtained from commercial sources. Inoue, and S. Mitsuhashi, personal communication). Re- Determination of hydrophobicity of quinolones. Hydropho- cently, we found that the bacterial outer membrane penetra- bicity of quinolones was determined by a previously de- tion mechanisms of new quinolones differed from those of scribed method (13). Solutions (10 ,ug/ml) of quinolones were old quinolones such as nalidixic and piromidic acids (13). made in 0.1 M phosphate buffer (pH 7.2). After shaking with To study the mechanisms of resistance to norfloxacin, the an equal volume of n-octanol at 25°C for 48 h and centrifug- first-developed new quinolone, spontaneous norfloxacin- ing at 1,870 x g for phase separation, the concentrations of resistant mutants were isolated from E. coli K-12 and their quinolones in the aqueous phase were determined by a properties were investigated. Three classes of mutants spectrophotometric assay. The partition coefficients (P) showed less susceptibility to norfloxacin; one class appeared were expressed as the ratio of the amount of compound in to consist of gyrA mutants, while the other two were novel the n-octanol phase to that in the aqueous phase. mutants that showed alteration in norfloxacin uptake. In this Media. Antibiotic medium 3, Mueller-Hinton medium, report we describe the biochemical and genetic properties of Mueller-Hinton agar, and nutrient agar were purchased from these new mutants in detail. Difco Laboratories, Detroit, Mich. L-broth and L-agar were (This work was presented in part at the 14th International prepared as described previously (22). Minimal medium Congress of Chemotherapy, Kyoto, Japan, 23-28 June (citrate-free minimal A medium) (6) contained 0.5% sugar 1985.) (glucose, galactose, or lactose) and was supplemented with amino acid (1 mM), if necessary. MATERIALS AND METHODS Measurement of susceptibility to antimicrobial agents and other chemical agents. MICs were determined by the agar Bacterial strains and phages. Bacterial strains and phages dilution method (18). An overnight culture of the bacterial used in this study are listed in Table 1. Spontaneous norflox- strain in Mueller-Hinton broth was diluted 100-fold with acin-resistant mutants (KEA12, KEA13, KEA16) were iso- fresh broth, and 5 ,ul of the bacterial suspension (about 5 x 106 cells per ml) was inoculated with an inoculator * Corresponding author. (Microplanter; Sakuma Seisakusho, Tokyo, Japan) onto 248 VOL. 30, 1986 NORFLOXACIN-RESISTANT MUTANTS OF E. COLI K-12 249 TABLE 1. Bacterial strains and phages used in this study KE7 (OmpC deficient) and strain KEll (OmpF deficient), E. coli K-12 which have been described previously (13). derivative or Genotype or phenotype Source Uptake of norfloxacin by the bacterial cells. The uptake of bacteriophage norfloxacin by bacterial cells was measured by a method described (13). Cells were grown to mid-log phase E. coli K-12 previously KL-16 Hfr relA thi B. Bachmann at 37°C in antibiotic medium 3, and the bacterial cell suspen- KEA12 Norfloxacin-resistant mutant This study sion (A570 = 0.7) was prepared with the same medium. of KL-16 Norfloxacin was added to the bacterial suspensions to a final KEA13 Norfloxacin-resistant mutant This study concentration of 10 ,ug/ml, and the cultures were incubated of KL-16 at 37°C with shaking. After the indicated times, 10 ml of the KEA16 Norfloxacin-resistant mutant This study culture was chilled, and the cells were sedimented by of KL-16 centrifugation and washed once in 2 ml of saline. The cells JC1552 F- argG gal his lacY leu B. Bachmann were then suspended in 1 ml of saline. The suspension was malA metB mtl strA supE immersed in boiling water for 7 min and then centrifuged. tonA trp tsx xyl KJC-1 glpT derivative of JC-1552 This study The concentration of norfloxacin in the supernatants was AB3505 F- argH galK his ilvD lacY B. Bachmann measured by a bioassay with E. coli NIHJ JC-2. or X malA metE mtl proA trp tsx xyl RESULTS LC607 F- ara lac leu lys metE K. Matsubara Isolation of norfloxacin-resistant mutants. Spontaneous proC purE str thi trp xyl mutants were isolated from E. coli Bacteriophages norfloxacin-resistant T2, T3, T4, This laboratory KL-16 by plating approximately 1010 CFUs of a late- T5, T7, P1 exponential-phase culture on nutrient agar plates containing Tula OmpF-specific phage S. Mizushima norfloxacin. Mutants showing less susceptibility to norflox- TuIb OmpC-specific phage S. Mizushima acin could be obtained at frequencies of 10-9 to 10-10 by selection on nutrient agar plates containing 0.05, 0.1, or 0.2 p,g of norfloxacin per ml. Mutants resistant to higher con- Mueller-Hinton agar plates containing serial twofold dilu- centrations of norfloxacin (0.39 pug/ml in nutrient agar) could tions of the agents. MICs were determined after 18 h of not be obtained by spontaneous single-step mutations. Mu- incubation at 37°C. tants with low-level resistance fell into three types according Genetic analysis. Conjugation, growth of bacteriophages, to their susceptibility to norfloxacin and nalidixic acid. Three and transduction were carried out as described by Miller representative mutants (KEA12, KEA13, KEA16) were (23). The procedure for interrupted mating was as described chosen for further study. by Curtiss (5). Acquisition of glpT+ after transduction was Susceptibility to quinolones and other chemical agents. The selected for by growth on minimal agar plates supplemented MIC was determined for quinolones (Table 2) and other with 0.4% L-a-glycerolphosphate as the sole carbon source. agents, including various antibiotics (Table 3). Strain KEA12 Phage sensitivity test. Phage susceptibility was determined showed especially high resistance to nalidixic and piromidic by a spot test (11). Bacteria (approximately 2 x 108 cells) acids. The MICs of norfloxacin and other new quinolones were mixed with 3 ml of L-broth containing 0.7% (wt/vol) such as ciprofloxacin, ofloxacin, and AM-833 for KEA12 agar (45°C) and poured over the surface of an L-agar plate. were increased eightfold over those of KL-16. Mutant After 20 min, bacteriophage suspensions (about 1010 PFU) KEA12 showed no changes in susceptibility to other antimi- were spotted onto the plate with an inoculator. The plates crobial agents, dyes, or detergents. Strain KEA13 showed were then incubated at 37°C for 24 h prior to scoring. low-level resistance to all the quinolones that were tested. Hydrophobicity of bacterial cell surface. Bacterial cell This mutant also showed a slight but reproducible increase in surface hydrophobicity was measured by a modification of resistance to ampicillin, chloramphenicol, cloxacillin, the method of Rosenberg et al. (24). The bacteria were novobiocin, and tetracycline and a larger increase in resist- grown at 37°C with shaking in antibiotic medium 3.
Recommended publications
  • 1057-1064, 1984 the Effect of Pipemidic Acid on The
    Microbiol. Immunol. Vol. 28 (9), 1057-1064, 1984 The Effect of Pipemidic Acid on the Growth of a Stable L-Form of •ôNH•ôStaphylococcus aureus•ôNS•ô Kunihiko YABU,*,1 Hiromi ToMizu,1 and Yayoi KANDA2 1 Department of Biology, Hokuriku University School of Pharmacy, Kanazawa-machi, Kanazawa, Ishikawa ,920-11, and 2Department of Microbiology, Teikyo University School of Medicine, Kaga 2-chome, Ilabashi-ku, Tokyo 173 (Accepted for publication, June 12, 1984) Bacterial L-forms usually display spherical forms in an osmotically protective medium and seem to lack the typical binary fission process of cellular division ob servedin most bacteria (7). Although various modes of replication, such as budding binary fission, and release of elementary bodies from large bodies have been observed by light and electron microscopy (2, 5, 16), little is known about the processes involved in replication of L-forms. In the course of an experiment designed to test the effect of DNA synthesis inhibitors on the growth of a stable L-form of •ôNH•ôStaphylococcus•ôNS•ôaureus which grows in liquid medium, it was found that pipemidic acid, a synthetic antibacterial agent structurally related to nalidixic acid (13), induced a marked morphological altera tionat growth inhibitory concentrations. This study was initiated in an attempt to clarify the mechanism of replication of stable L-forms by analyzing the mor phologicalalteration caused by pipemidic acid. The stable L-form used was isolated as follows. S. •ôNH•ôaureus•ôNS•ôFDA 209P was grown in 10ml of Brain Heart Infusion broth (Difco) at 37C. The culture grown at 5•~105 colony-forming units (CFU) per ml was washed with saline by filtration and suspended in saline containing 100ƒÊg of N-methyl-N'-nitro-N-nitrosoguanidine per nil.
    [Show full text]
  • Resistance Pattern of Coagulase Positive Staphylococcus Aureus Clinical Isolates from Asir Region, Kingdom of Saudi Arabia
    Journal of Microbiology and Antimicrobials Vol. 3(4), pp. 102-108, April 2011 Available online http://www.academicjournals.org/JMA ISSN 2141-2308 ©2011 Academic Journals Full Length Research Paper Resistance pattern of coagulase positive Staphylococcus aureus clinical isolates from Asir region, Kingdom of Saudi Arabia Mohamed E. Hamid Department of Microbiology, College of Medicine, King Khalid University, P. O. Box 641, Abha, Kingdom of Saudi Arabia. E-mail: [email protected]. Accepted 6 April, 2011 The objectives of this study were to determine the prevalence of methicillin resistant coagulase positive Staphlococcus aureus (MRSA) infections in two major hospitals in Asir region, Kingdom of Saudi Arabia and to compare it with the community-acquired infections. Two hundreds and ten coagulase positive S. aureus recovered from 9831 specimens from various infections at Asir Central Hospital and Abha General Hospital, KSA (Kingdom of Saudi Arabia), were tested against 44 commonly used antibacterial agents. One hundred of the isolates were from hospital-acquired infections, 100 from community-acquired infections and 10 isolates were collected from the hospital environment. All isolates were found resistant to aztreonam, colistin, mecillinam, metronidazole, polymyxin B and nalidixic acid but were sensitive to vancomycin, nitrofurantoin and novobiocin. Various levels of resistant were recorded for the remaining antibiotics. High resistance to antimicrobial agents was detected among hospital acquired infections compared to community acquired infections (p<0.01). The resistance rates of S. aureus to antimicrobial agents among hospital acquired infections isolates were significantly higher (p<0.05) than community acquired infections. This implies that hospital environment is a strong risk factor for the prevalence of MRSA in the hospitalized patients, visitors, and hospital staff with potential risk of spreading to the community.
    [Show full text]
  • Microbiological Air Quality and Drug Resistance in Airborne Bacteria Isolated from a Waste Sorting Plant Located in Poland—A Case Study
    microorganisms Article Microbiological Air Quality and Drug Resistance in Airborne Bacteria Isolated from a Waste Sorting Plant Located in Poland—A Case Study Ewa Br ˛agoszewska 1,* , Izabela Biedro ´n 2 and Wojciech Hryb 1 1 Faculty of Power and Environmental Engineering, Department of Technologies and Installations for Waste Management, Silesian University of Technology, 18 Konarskiego St., 44-100 Gliwice, Poland; [email protected] 2 Institute for Ecology of Industrial Areas, Environmental Microbiology Unit, 6 Kossutha St., 40-844 Katowice, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-322-372-762 Received: 13 December 2019; Accepted: 29 January 2020; Published: 31 January 2020 Abstract: International interests in biological air pollutants have increased rapidly to broaden the pool of knowledge on their identification and health impacts (e.g., infectious, respiratory diseases and allergies). Antibiotic resistance and its wider implications present us with a growing healthcare crisis, and an increased understanding of antibiotic-resistant bacteria populations should enable better interpretation of bioaerosol exposure found in the air. Waste sorting plant (WSP) activities are a source of occupational bacterial exposures that are associated with many health disorders. The objectives of this study were (a) to assess bacterial air quality (BAQ) in two cabins of a WSP: preliminary manual sorting cabin (PSP) and purification manual sorting cabin (quality control) (QCSP), (b) determine the particle size distribution (PSD) of bacterial aerosol (BA) in PSP, QCSP, and in the outdoor air (OUT), and (c) determine the antibiotic resistance of isolated strains of bacteria. Bacterial strains were identified on a Biolog GEN III (Biolog, Hayward, CA, USA), and disc diffusion method for antimicrobial susceptibility testing was carried out according to the Kirby–Bauer Disk Diffusion Susceptibility Test Protocol.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Antibiotic Sensitivity of Bacterial Pathogens Isolated from Bovine Mastitis Milk
    Content of Research Report A. Project title: Antibiotic Sensitivity of Bacterial Pathogens Isolated From Bovine Mastitis Milk B. Abstract: Antibiotic sensitivity of bacteria isolated from bovine milk samples was investigated. The 18 antibiotics that were evaluated (e.g., penicillin, novobiocin, gentamicin) are commonly used to treat various diseases in cattle, including mastitis, an inflammation of the udder of dairy cows. A common concern in using antibiotics is the increase in drug resistance with time. This project studies if antibiotic resistance is a threat to consumers of raw milk products and if these antibiotics are still effective against mastitis pathogens. The study included isolating and culturing bacteria from quarter milk samples (n=205) collected from mastitic dairy cows from farms in Chino and Ontario, CA. The isolated bacteria were tested for sensitivity to antibiotics using the Kirby Bauer disk diffusion method. The prevalence (%) of resistance to the individual antibiotics was reported. Resistance to penicillin was 45% which may support previous data on penicillin-resistant bacteria, especially Staphylococcus and Streptococcus. Resistance rates (%) for oxytetracycline (26.8%) and tetracycline (22.9%) were low compared to previous studies but a trend was seen in our results that may support concerns of emerging resistance to tetracyclines in both gram- positive and gram-negative bacteria. Similarly, 31.9% of bacterial isolates showed resistance to erythromycin which is at least 30% less than in reported literature concerning emerging resistance to macrolides. More numbers (%) that should be noted are cefazolin (26.3%), ampicillin (29.7%), novobiocin (33.0%), polymyxin B (31.5%), and resistance ranging from 9­ 18% for the other antibiotics.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • NOTES in Vitro Activities of Norfloxacin and Ciprofloxacin Against
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1984, p. 94-96 Vol. 26, No. 1 0066-4804/84/070094-03$02.00/0 Copyright C 1984, American Society for Microbiology NOTES In Vitro Activities of Norfloxacin and Ciprofloxacin Against Mycobacterium tuberculosis, M. avium Complex, M. chelonei, M. fortuitum, and M. kansasii J. DOUGLAS GAY, DONALD R. DEYOUNG, AND GLENN D. ROBERTS* Section of Clinical Microbiology, Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905 Received 28 November 1983/Accepted 4 April 1984 The activities of ciprofloxacin and norfloxacin against 100 mycobacteria isolates were studied in vitro by the 1% standard proportion method. Ciprofloxacin was more active against M. tuberculosis and M. fortuitum with MICs of 1.0 and 0.25 ,ug/ml, respectively, against 90% of isolates; norfloxacin had MICs of 8.0 and 2.0 ,ug/ml, respectively, against 90% of isolates. Nalidixic acid and other heterocyclic carbonic acid deriva- studied. The organisms were taken from the Mayo Clinic tives have been used primarily in the treatment of urinary stock culture collection, which included recent clinical iso- tract infections for many years. The compounds of this lates. Stock cultures were maintained on Middlebrook 7H10 general group include nalidixic acid, oxolinic acid, pipemidic agar slants (Difco Laboratories, Detroit, Mich.) and were acid, cinoxacin, and rosoxacin. Two new substances in this subcultured monthly. The identification of isolates was series which have been recently synthesized are norfloxacin based on standard biochemical tests (17) and gas-liquid (6) (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[ 1-piperazinyl ]-3- chromatography (16).
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis
    separations Review On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis Victoria Samanidou *, Dimitrios Bitas, Stamatia Charitonos and Ioannis Papadoyannis Laboratory of Analytical Chemistry, University of Thessaloniki, GR 54124 Thessaloniki, Greece; [email protected] (D.B.); [email protected] (S.C.); [email protected] (I.P.) * Correspondence: [email protected]; Tel.: +30-2310-997698; Fax: +30-2310-997719 Academic Editor: Frank L. Dorman Received: 2 February 2016; Accepted: 26 February 2016; Published: 4 March 2016 Abstract: The widespread use of antibiotics in veterinary practice and aquaculture has led to the increase of antimicrobial resistance in food-borne pathogens that may be transferred to humans. Global concern is reflected in the regulations from different agencies that have set maximum permitted residue limits on antibiotics in different food matrices of animal origin. Sensitive and selective methods are required to monitor residue levels in aquaculture species for routine regulatory analysis. Since sample preparation is the most important step, several extraction methods have been developed. In this review, we aim to summarize the trends in extraction of several antibiotics classes from shrimps and give a comparison of performance characteristics in the different approaches. Keywords: sample preparation; extraction; aquaculture; shrimps; chromatography; antibiotics 1. Introduction According to FAO (CWP Handbook of Fishery Statistical Standards, Section J: AQUACULTURE), “aquaculture is the farming of aquatic organisms: fish, mollusks, crustaceans, aquatic plants, crocodiles, alligators, turtles, and amphibians. Farming implies some form of intervention in the rearing process to enhance production, such as regular stocking, feeding, protection from predators, etc.”[1]. Since 1960, aquaculture practice and production has increased as a result of the improved conditions in the aquaculture facilities.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,097,607 B2 Cabana Et Al
    USO08097607B2 (12) United States Patent (10) Patent No.: US 8,097,607 B2 Cabana et al. (45) Date of Patent: *Jan. 17, 2012 (54) LOW DOSE RIFALAZIL COMPOSITIONS Emori et al., “Evaluation of in Vivo Therapeutic Efficacy of a New Benzoxazinorifamycin, KRM-1648, in SCID Mouse Model for Dis (76) Inventors: Bernard E. Cabana, Montgomery seminated Mycobacterium avium Complex Infection.” International Village, MD (US); Arthur F. Michaelis, Journal of Antimicrobial Agents 10(1):59 (1998). Devon, PA (US); Gary P. Magnant, Fujii et al., “In Vitro and In Vivo Antibacterial Activities of KRM Topsfield, MA (US); Chalom B. 1648 and KRM-1657, New Rifamycin Derivatives.” Antimicrobial Sayada, Luxembourg (LU) Agents and Chemotherapy 38: 1118, (1994). Gidoh et al., “Bactericidal Action at Low Doses of a New Rifamycin (*) Notice: Subject to any disclaimer, the term of this Derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) patent is extended or adjusted under 35 Benzoxazinorifamycin (KRM-1648) on Mycobacterium leprae U.S.C. 154(b) by 447 days. Inoculated into Ffootpads of Nude Mice.” Leprosy Review 63(4):319 This patent is Subject to a terminal dis (1992). claimer. Heep et al., “Detection of Rifabutin Resistance and Association of rpoB Mutation S with Resistance to Four Rifamycin Derivatives in Helicobacter pylori.” Journal of Clinical Microbiology & Infectious (21) Appl. No.: 10/668,792 Diseases 21:143 (2002). Hirara et al., “In Vitro and in Vivo Activities of the (22) Filed: Sep. 23, 2003 Benezoxazinorifamycin KRM-1648 Against Mycobacterium tuber (65) Prior Publication Data culosis,” Antimocrobial Agents and Chemotherapy 39 (10):2295 (1995). US 2004/O15784.0 A1 Aug.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Sensitivity in Vitro of the Providence And
    J Clin Pathol: first published as 10.1136/jcp.11.3.270 on 1 May 1958. Downloaded from J. clin. Pat/i. (1958), 11, 270. THE SENSITIVITY IN VITRO OF THE PROVIDENCE GROUP OF ENTERIC BACTERIA TO 14 ANTIBIOTICS AND NITROFURANTOIN BY J. E. MIDDLETON From the Louis Jenner Laboratory, St. Thomas's Hospital and Medical School, London (RECEIVED FOR PUBLICATION JANUARY 8, 1958) During the course of an investigation into the oxytetracycline (100 Pg.), chloramphenicol (100 p-g.), antibiotic sensitivity of strains of the Proteus polymyxin (500 u.), and nitrofurantoin 10,000 pg.). per paper disc or group of bacteria isolated from infections of the (The concentration of each drug test tablet is given in brackets.) A zone of inhi- urinary tract (Middleton, 1957) a few strains of bition of growth 10 mm. or more in diameter were examined. This the Providence group also was considered to indicate sensitivity to the anti- group of the Enterobacteriaceae called type 29911 biotics, the discs or test tablets being 5 mm. in by Stuart, Wheeler, Rustigian, and Zimmerman diameter. Any inhibition of growth round the nitro- (1943), and named Providence by Kauffmann furantoin test tablet was taken to indicate that the (1951), has close affinities in many characteristics organism was sensitive to the drug. with the Proteus group (Singer and Bar-Chay, A few strains were also tested by the serial dilution copyright. 1954), and a similarity between strains of the two technique against streptomycin, tetracycline, and ml.) of a groups was found here in their common resistance chloramphenicol. A standard drop (0.02 dilution of an overnight broth culture was to many antibiotics in vitro.
    [Show full text]